Home / Healthcare-IT / Diabetic M

Diabetic Macular Edema - Pipeline Insights, Recent Developments, Major Players and Review

Diabetic Macular Edema: Overview

Diabetic macular edema (DME), is a type of eye condition in which the blood vessels in the eye gets badly affected. As a result of this medical condition, fluid can leak from the blood vessels and it flows towards the middle of the retina. The retina is a thin layer of tissue that borders the interior of the eye's rear wall. You may lose some or all of your site if it's not addressed.

As per the National Eye Institute reports, the DME generally affects around 7.5 lakhs of the US population. According to the research, up to 10% of patients with diabetes may suffer from the problem. In terms of global statistics, the International Diabetes Federation (IDF) estimates that diabetic macular edema affects more than 28 million people globally.

Report Key Takeaways

Some of the recommended treatments for the DME:

Focal Laser

Laser light is used in this type of treatment to completely destroy the leaking blood vessels in the eyes. This type of laser therapy usually does not cause any discomfort. In such types of treatment, it may leave a persistent blind patches. However, it also aids in the slowing or halting of the formation of new blood vessels, which could further impair vision. It is helpful in saving the remaining vision and it may even aid in improving it marginally.


In this treatment, injections of steroids into the eye are used over a certain period of time in order to reduce the DME. Steroids may also be used when a person is unable to tolerate numerous injections. However, this treatment may increase the risk of cataracts and increased intraocular pressure in the long run.


If the vitreous is dragging on the macula, your doctor is most likely to recommend undergoing surgery. The macula is restored to its natural form through a process termed vitrectomy in this example.

Some of the Drugs recommended for DME:

  • KSI-301: Kodiak Sciences
  • RZ402: Rezolute
  • THR-687: Oxurion
  • UBX 1325: Ascentage Pharma
  • APX3330: Ocuphire Pharma

Recent Developments related to Diabetic Macular Edema

  • Oxurion NV, a leading biopharmaceutical company that develops next-generation standard-of-care ophthalmic treatments, announced major findings from Part A of its Phase 2 study of THR-687, an integrin antagonist, for the treatment of diabetic macular edema.
  • Roche Canada officially announced that they have received approval from Health Canada for VABYSMO®, which will be used for the treatment of diabetic macular edema. The DME has emerged as one of the primary causes of vision loss in the Canadian population.

Major Players Working on Diabetic Macular Edema

Some of the leading companies dealing with the research and development activities related to the diabetic macular edema industry include Novartis, Momenta Pharmaceuticals, Adverum Biotechnologies, Inc., Roche, and Kodiak Sciences Inc.

These industry dominant companies are forming strategic alliances to conduct a higher level of R&D activities to identify major risks and possible solutions that could play a big role in managing DME.


Key Reasons to Purchase This Report

  • The pipeline insights offer a broader outlook of major treatments for DME which covers the entire product development cycle, covering all product types, clinical and non-clinical stages, and product development stages.
  • The pipeline’s assessment part sheds light on the DME commercial assessment as well as a clinical assessment of the pipeline drugs in development.
  • The pipeline insight features detailed information on acquisitions, collaborations, partnerships, and licensing, along with a special emphasis on the evaluation of new DME treatments.

Diabetic patients are usually at a higher risk that they may get diagnosed with DME certain period of time. A diabetic's vision should be examined at least once a year, or as prescribed by their eye doctor. Double vision, fuzzy vision, and an increase in eye floaters are all signs of visual alterations.

In the beginning, your eye doctor will conduct a thorough examination of vision exam before proceeding with the diagnosis part of diabetic macular edema. To conduct a better examination of your retina and find signs of damage, they will also need to widen your pupils

Some people respond to a single therapy entirely, while others require numerous treatments over a longer period of time.

Asia countries, The U.S., The U.K., and Canada are among the countries that mostly register the cases of diabetic macular edema.

The blood vessels in your eyes become weaker when your blood sugar level rises. In your retina, the light-sensitive area at the back of your eye, this can cause them to leak or grow out of control.

Choose License Type
Published Date:  Jun 2022
Category:  Healthcare-IT
Report ID:   60555
Report Format:   PDF
Pages:   85
Rating:    4.8 (15)
Connect With Us
24/7 Research Support